Immunovant Inc (IMVT)

Mar 12, 2025

Immunovant director Andrew Fromkin sells $156,768 in stock By Investing.com - Investing.com South Africa

Mar 12, 2025

Mar 11, 2025

Immunovant director Andrew Fromkin sells $156,768 in stock - Investing.com

Mar 11, 2025

Mar 11, 2025

Immunovant’s (IMVT) Buy Rating Reaffirmed at Guggenheim - Defense World

Mar 11, 2025

Mar 10, 2025

(IMVT) Investment Report - Stock Traders Daily

Mar 10, 2025

Mar 07, 2025

Commit To Buy Immunovant At $15, Earn 15.1% Annualized Using Options - Nasdaq

Mar 07, 2025

Mar 07, 2025

Cantor Fitzgerald Estimates Immunovant FY2025 Earnings - Defense World

Mar 07, 2025

Mar 07, 2025

Brokerages Set Immunovant, Inc. (NASDAQ:IMVT) PT at $43.55 - Defense World

Mar 07, 2025

Mar 06, 2025

A stock that deserves closer examination: Immunovant Inc (IMVT) - US Post News

Mar 06, 2025

Mar 06, 2025

Immunovant (NASDAQ:IMVT) Raised to “Strong-Buy” at Cantor Fitzgerald - Defense World

Mar 06, 2025

Mar 05, 2025

Immunovant, Inc. (IMVT): Among The Stocks With At Least $30 Million In Insider Spending Recently - Yahoo Finance

Mar 05, 2025

Mar 05, 2025

10 Stocks With At Least $30 Million In Insider Spending Recently - Insider Monkey

Mar 05, 2025

Mar 05, 2025

Comparing Immunovant (NASDAQ:IMVT) & OKYO Pharma (NASDAQ:OKYO) - Defense World

Mar 05, 2025

Mar 04, 2025

Immunovant Inc (NASDAQ: IMVT) Stock Forecast: Bearish Views Expect -176.57 Percent Drop In 2025 - Stocks Register

Mar 04, 2025

Mar 04, 2025

Rhumbline Advisers Boosts Holdings in Immunovant, Inc. (NASDAQ:IMVT) - Defense World

Mar 04, 2025

Mar 04, 2025

Immunovant (NASDAQ:IMVT) Now Covered by Jefferies Financial Group - Defense World

Mar 04, 2025

Mar 04, 2025

Immunovant CEO Peter Salzmann sells $208,899 in stock - MSN

Mar 04, 2025

Mar 03, 2025

Immunovant stock hits 52-week low at $19.04 amid market challenges By Investing.com - Investing.com South Africa

Mar 03, 2025

Mar 03, 2025

Immunovant stock hits 52-week low at $19.04 amid market challenges - Investing.com Australia

Mar 03, 2025

Mar 03, 2025

Jefferies Initiates Immunovant at Hold With $20 Price Target -March 03, 2025 at 07:25 am EST - Marketscreener.com

Mar 03, 2025

Mar 03, 2025

Jefferies sets Immunovant stock hold rating, $20 price target By Investing.com - Investing.com Canada

Mar 03, 2025

Mar 03, 2025

FY2025 EPS Estimates for Immunovant Cut by Zacks Research - Defense World

Mar 03, 2025

Feb 28, 2025

(IMVT) Technical Pivots with Risk Controls - Stock Traders Daily

Feb 28, 2025

Feb 27, 2025

Immunovant’s Promising Pipeline and Strategic Focus Drive Buy Rating - TipRanks

Feb 27, 2025

Feb 27, 2025

Taking a look at what insiders are doing to gauge the Immunovant Inc (IMVT)’s direction - Knox Daily

Feb 27, 2025

Feb 27, 2025

FY2025 EPS Estimates for Immunovant Cut by Lifesci Capital - Defense World

Feb 27, 2025

Feb 25, 2025

Principal Financial Group Inc. Lowers Stake in Immunovant, Inc. (NASDAQ:IMVT) - Defense World

Feb 25, 2025

Feb 24, 2025

Have Insiders Sold Immunovant Shares Recently? - Simply Wall St

Feb 24, 2025

Feb 23, 2025

Immunovant, Inc. (IMVT): the Most Oversold Pharma Stock to Buy According to Analysts - Insider Monkey

Feb 23, 2025

Feb 22, 2025

10 Oversold Pharma Stocks to Buy According to Analysts - Insider Monkey

Feb 22, 2025

Feb 22, 2025

Immunovant, Inc. (IMVT): Is It The Most Oversold Healthcare Stock to Buy Now? - Insider Monkey

Feb 22, 2025

Feb 22, 2025

Immunovant CEO Peter Salzmann sells $322,057 in stock to cover tax obligations - Investing.com Canada

Feb 22, 2025

Feb 22, 2025

Immunovant's chief medical officer Macias sells $42,867 in stock By Investing.com - Investing.com Australia

Feb 22, 2025

Feb 22, 2025

Immunovant’s chief medical officer Macias sells $42,867 in stock By Investing.com - Investing.com Nigeria

Feb 22, 2025

Feb 21, 2025

Immunovant CEO Peter Salzmann sells $322,057 in stock to cover tax obligations By Investing.com - Investing.com South Africa

Feb 21, 2025

Feb 21, 2025

Immunovant's chief medical officer Macias sells $42,867 in stock - Investing.com

Feb 21, 2025

Feb 21, 2025

Immunovant Executives Sell Shares to Cover Tax Obligations - TradingView

Feb 21, 2025

Feb 19, 2025

12 Most Oversold Healthcare Stocks to Buy Now - Insider Monkey

Feb 19, 2025

Feb 19, 2025

Immunovant, Inc. (IMVT): Among Stocks Insiders Spent The Most Money On Recently - MSN

Feb 19, 2025

Feb 19, 2025

Biotech Kingpin: Why Insiders Are Betting Big on Immunovant - Reporteros del Sur -

Feb 19, 2025

Feb 19, 2025

ABC Arbitrage SA Invests $734,000 in Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat

Feb 19, 2025

Feb 18, 2025

Banque Pictet & Cie SA Sells 13,440 Shares of Immunovant, Inc. (NASDAQ:IMVT) - MarketBeat

Feb 18, 2025

Feb 17, 2025

(IMVT) Investment Analysis and Advice - Stock Traders Daily

Feb 17, 2025

Feb 14, 2025

Immunovant Inc [IMVT] Shares Rise 3.33 % on Thursday - Knox Daily

Feb 14, 2025

Feb 14, 2025

Guggenheim cuts Immunovant stock target to $44, maintains Buy - MSN

Feb 14, 2025

Feb 14, 2025

Immunovant (NASDAQ:IMVT) Given New $44.00 Price Target at Guggenheim - MarketBeat

Feb 14, 2025

Feb 13, 2025

Immunovant's Key Batoclimab Trial Catalysts Expected By MarchCan The Stock Bounce Back? - RTTNews

Feb 13, 2025